Clinical Trial Update: Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study [Phase 4]

View source ↗

Summary

Phase 4 interventional prospective study assessing predictors of response to aflibercept and aqueous cytokine levels in patients with persistent diabetic macula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Unity Health Toronto | Conditions: Diabetic Macular Edema | Phase 4 | Status: UNKNOWN